// App-Quantinova.ai

5002.0 : SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Daniel Yick Chin Heng

  • Jae-Lyun Lee

  • Mathilde Cancel

  • Remy B Verheijen

  • Anders Mellemgaard

  • Lone Ottesen

  • Melanie M. Frigault

  • Anne L'Hernault

  • Zsolt Szijgyarto

  • Sabina Signoretti

  • Laurence Albiges

Medical Centers

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Department of Radiation Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Hopital Bretonneau, Tours, France

  • Oncology R&D, AstraZeneca, Boston, MA

  • Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Hepatocyte growth factor

Drug/Treatment

  • Savolitinib

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • NA

Study Id's

  • NCT03091192

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved